https://www.nasdaq.com/press-release/ayala-pharmaceuticals-announces-key-business-objectives-for-2022-2022-01-04
https://www.nasdaq.com/press-release/ayala-pharmaceuticals-reports-third-quarter-2021-financial-results-and-provides
https://www.nasdaq.com/press-release/ayala-pharmaceuticals-to-present-at-jefferies-london-healthcare-conference-2021-11-10
https://www.nasdaq.com/press-release/ayala-pharmaceuticals-announces-publication-highlighting-clinical-activity-of-its
https://www.nasdaq.com/press-release/ayala-pharmaceuticals-presents-preliminary-clinical-data-from-the-ongoing-phase-2
https://www.nasdaq.com/press-release/ayala-pharmaceuticals-to-participate-in-upcoming-virtual-investor-conferences-2021-09
https://www.nasdaq.com/press-release/ayala-pharmaceuticals-to-present-clinical-data-from-ongoing-phase-2-accuracy-trial
https://www.nasdaq.com/press-release/ayala-pharmaceuticals-reports-second-quarter-2021-financial-results-and-provides
https://www.nasdaq.com/press-release/ayala-pharmaceuticals-to-present-at-ladenburg-thalmann-healthcare-conference-2021-07
https://www.nasdaq.com/press-release/ayala-pharmaceuticals-to-participate-in-upcoming-virtual-investor-conferences-2021-05
https://www.nasdaq.com/press-release/ayala-pharmaceuticals-reports-first-quarter-2021-financial-results-and-provides
https://www.nasdaq.com/press-release/ayala-pharmaceuticals-announces-first-patient-dosed-in-phase-1-clinical-trial-of
https://www.nasdaq.com/press-release/ayala-pharmaceuticals-reports-full-year-2020-financial-results-and-provides-business
https://www.nasdaq.com/press-release/ayala-pharmaceuticals-to-participate-in-upcoming-virtual-investor-conferences-2021-03
https://www.nasdaq.com/press-release/ayala-pharmaceuticals-announces-%2425-million-strategic-financing-2021-02-19
https://www.nasdaq.com/press-release/ayala-pharmaceuticals-announces-first-patient-dosed-in-phase-2-tenacity-clinical
https://www.nasdaq.com/press-release/ayala-pharmaceuticals-to-present-at-noble-capital-markets-17th-annual-small-microcap
https://www.nasdaq.com/press-release/ayala-pharmaceuticals-to-present-at-the-virtual-h.c.-wainwright-bioconnect-conference
https://www.nasdaq.com/press-release/ayala-pharmaceuticals-to-accelerate-development-of-al102-for-the-treatment-of-desmoid
https://www.nasdaq.com/press-release/ayala-pharmaceuticals-reports-third-quarter-2020-financial-results-and-provides
https://www.nasdaq.com/press-release/ayala-pharmaceuticals-to-participate-in-upcoming-virtual-investor-conferences-2020-11
https://www.nasdaq.com/press-release/ayala-pharmaceuticals-presents-positive-interim-data-from-phase-2-accuracy-trial-of
https://www.nasdaq.com/press-release/ayala-pharmaceuticals-to-host-virtual-kol-event-reviewing-interim-data-presented-at
https://www.nasdaq.com/press-release/ayala-pharmaceuticals-to-present-at-upcoming-investor-conferences-2020-09-08
https://www.nasdaq.com/press-release/ayala-pharmaceuticals-announces-the-appointment-of-vered-bisker-leib-ph.d.-to-its
https://www.nasdaq.com/press-release/ayala-pharmaceuticals-reports-second-quarter-2020-financial-results-and-provides
https://www.nasdaq.com/press-release/ayala-pharmaceuticals-to-present-updated-data-from-ongoing-phase-2-accuracy-trial-of
https://www.nasdaq.com/press-release/ayala-pharmaceuticals-reports-first-quarter-2020-financial-results-and-provides
